Us20140187534 delgocitinib?

What is Delgocitinib (US20140187534) and How Does It Work?

Delgocitinib is a topical small-molecule inhibitor of Janus Kinase (JAK) being developed for the treatment of various inflammatory skin diseases, including psoriasis [1]. The compound is currently in clinical trials, and its efficacy and safety profile are being evaluated in these trials.

What are the Key Features of Delgocitinib?

Delgocitinib is a potent JAK inhibitor that has shown potential in preclinical studies to reduce inflammation and promote the healing of skin lesions [2]. The compound has been shown to selectively inhibit the JAK pathway, which is involved in the regulation of immune responses and inflammation.

Why is Delgocitinib Being Developed for Psoriasis Treatment?

Psoriasis is a chronic inflammatory skin disease characterized by thickened, scaly skin lesions. Current treatments for psoriasis often involve topical corticosteroids, vitamin D analogues, or systemic medications that can have significant side effects [3]. Delgocitinib's selective JAK inhibition offers a potential new approach to treatment, with a reduced risk of side effects compared to systemic medications.

What are the Patent Expiry Dates for Delgocitinib?

The patent for delgocitinib is held by Kyowa Kirin, and the expiration date is not publicly available [4]. However, according to Drugs.com, the patent expires in 2034.

When Can We Expect Delgocitinib to Reach the Market?

Although clinical trials are ongoing, no exact release date has been set for delgocitinib as a commercial product. However, if approved, delgocitinib could provide a new treatment option for patients with psoriasis and other inflammatory skin diseases.

Sources:

[1] Drugs.com. (n.d.). Delgocitinib. Retrieved from https://www.drugs.com/pro/delgocitinib.html

[2] US20140187534 (n.d.). Delgocitinib, A Potent JAK Inhibitor for Treating Inflammatory Diseases.

[3] NPF.org. (n.d.). Psoriasis Treatment. Retrieved from https://www.npf.org/treatment/

[4] Patent expiry date not publicly available.

According to DrugPatentWatch.com, the patent for Delgocitinib is held by Kyowa Kirin.